bortezomib + decitabine

A combination therapy consisting of the proteasome inhibitor bortezomib and the hypomethylating agent decitabine. This regimen is being investigated for the treatment of acute myeloid leukemia (AML), including relapsed, refractory, or previously untreated cases. Bortezomib inhibits the 26S proteasome, leading to the disruption of protein homeostasis and induction of apoptosis in cancer cells. Decitabine is a cytidine antimetabolite that incorporates into DNA and inhibits DNA methyltransferase, resulting in DNA hypomethylation and the reactivation of tumor suppressor genes. The combination aims to enhance the antileukemic effect through synergistic mechanisms, where proteasome inhibition may sensitize cells to the epigenetic modifications induced by decitabine.

Other names

bortezomib and decitabinedecitabine and bortezomibVelcade and Dacogen